Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI
- Analysis of 2 Cases / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 52-56, 2019.
Artigo
em Chinês
| WPRIM
| ID: wpr-772331
ABSTRACT
Tyrosine kinase inhibitor (TKI) have been proved to be effective in the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitive mutation, which is superior to chemotherapy. However, there are still some patients with sensitive mutations have primary drug resistance. It may be related to the coexistence of susceptible and resistant mutations of EGFR gene, downstream mutations of EGFR pathway, MET amplification and BIM deletion polymorphism. We present 2 cases of primary drug resistance and analyze the reasons.
.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Diagnóstico por Imagem
/
Resultado do Tratamento
/
Evolução Fatal
/
Carcinoma Pulmonar de Células não Pequenas
/
Progressão da Doença
/
Resistencia a Medicamentos Antineoplásicos
/
Usos Terapêuticos
/
Inibidores de Proteínas Quinases
/
Tratamento Farmacológico
/
Receptores ErbB
Tipo de estudo:
Estudo diagnóstico
Limite:
Humanos
/
Masculino
Idioma:
Chinês
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS